Changing mindsets about methotrexate in the rheumatology clinic to reduce side effects and improve adherence: a randomized controlled trial
Open Access
- 23 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Annals of Behavioral Medicine
- Vol. 59 (1)
Abstract
Background: Patients’ negative expectations about medication can exacerbate side effect burden leading to low adherence and persistence. A novel intervention involves targeting mindsets about non-severe symptoms; reframing them as encouraging signs of medication working. Purpose: This study aimed to assess whether a brief symptom-mindset intervention can improve symptom experience and adherence in patients starting methotrexate to treat an inflammatory rheumatic disease. Methods: A randomized controlled trial was conducted with patients starting methotrexate. Participants were randomly assigned (1:1) to a mindset intervention or standard information control condition. Symptom mindset was assessed after 4 weeks to check intervention efficacy. The primary outcome was symptom experience after 4 weeks. Secondary outcomes were adherence and motivation to take methotrexate (4 weeks), as well as continuation and C-reactive protein (12 weeks). Results: Forty-seven participants were randomly assigned to the intervention (n = 24) or control group (n = 23). All participants completed the study. After 4 weeks, compared to the control group, intervention participants endorsed more positive symptom mindsets, experienced less symptom burden (mean difference −2.70 [95% CI, −4.50, −0.90] P = .005), fewer general symptoms (3.53 [−6.99, .79] P = .045) and a similar number of methotrexate-specific symptoms (−0.79 [−2.29, 0.71] P = .295). The intervention group had better motivation and adherence to methotrexate at 4 weeks and better continuation, and C-reactive protein at 12 weeks than the control group. There was no difference in side effect attribution. Conclusions: In patients starting methotrexate, a mindset intervention reframing the role of non-severe side effects is a promising approach for improving symptom experience and early stage medication persistence.Keywords
This publication has 39 references indexed in Scilit:
- Psychosocial Interventions and Immune System FunctionJAMA Psychiatry, 2020
- Side effects of methotrexate therapy for rheumatoid arthritis: A systematic reviewEuropean Journal of Medicinal Chemistry, 2018
- Decreasing the Burden of Side Effects Through Positive Message Framing: an Experimental Proof-of-Concept StudyInternational Journal of Behavioral Medicine, 2018
- Mindsets Matter: A New Framework for Harnessing the Placebo Effect in Modern Medicine2018
- Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative SynthesisArthritis Care & Research, 2017
- Self-report measures of medication adherence behavior: recommendations on optimal useTranslational Behavioral Medicine, 2015
- Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registryBreast Cancer Research and Treatment, 2014
- Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohortClinical Rheumatology, 2014
- The Effect of Treatment History on Therapeutic Outcome: An Experimental ApproachJAMA Internal Medicine, 2013
- Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicinesArthritis Care & Research, 2010